key: cord-0723134-yzg18pg7
authors: Wilton, Thomas; Bujaki, Erika; Klapsa, Dimitra; Majumdar, Manasi; Zambon, Maria; Fritzsche, Martin; Mate, Ryan; Martin, Javier
title: Rapid Increase of SARS-CoV-2 Variant B.1.1.7 Detected in Sewage Samples from England between October 2020 and January 2021
date: 2021-06-15
journal: mSystems
DOI: 10.1128/msystems.00353-21
sha: 6dc5fb5c02b99374ad9d6afa940d0bef5a6706b0
doc_id: 723134
cord_uid: yzg18pg7

SARS-CoV-2 variants with multiple amino acid mutations in the spike protein are emerging in different parts of the world, raising concerns regarding their possible impact on human immune response and vaccine efficacy against the virus. Recently, a variant named lineage B.1.1.7 was detected and shown to be rapidly spreading across the UK since November 2020. As surveillance for these SARS-CoV-2 variants of concern (VOCs) becomes critical, we have investigated the use of environmental surveillance (ES) for the rapid detection and quantification of B.1.1.7 viruses in sewage as a way of monitoring its expansion that is independent on the investigation of identified clinical cases. Next-generation sequencing analysis of amplicons synthesized from sewage concentrates revealed the presence of B.1.1.7 mutations in viral sequences, first identified in a sample collected in London on 10 November 2020 and shown to rapidly increase in frequency to >95% in January 2021, in agreement with clinical data over the same period. We show that ES can provide an early warning of VOCs becoming prevalent in the population and that, as well as B.1.1.7, our method can detect VOCs B.1.351 and P.1, first identified in South Africa and Brazil, respectively, and other viruses carrying critical spike mutation E484K, known to have an effect on virus antigenicity. Although we did not detect such mutation in viral RNAs from sewage, we did detect mutations at amino acids 478, 490, and 494, located close to amino acid 484 in the spike protein structure and known to also have an effect on antigenicity. IMPORTANCE The recent appearance and growth of new SARS-CoV-2 variants represent a major challenge for the control of the COVID-19 pandemic. These variants of concern contain mutations affecting antigenicity, which raises concerns on their possible impact on human immune response to the virus and vaccine efficacy against them. Here, we show how environmental surveillance for SARS-CoV-2 can be used to help us understand virus transmission patterns and provide an early warning of variants becoming prevalent in the population. We describe the detection and quantification of variant B.1.1.7, first identified in southeast England in sewage samples from London (UK) before widespread transmission of this variant was obvious from clinical cases. Variant B.1.1.7 was first detected in a sample from early November 2020, with the frequency of B.1.1.7 mutations detected in sewage rapidly increasing to >95% in January 2021, in agreement with increasing SARS-CoV-2 infections associated with B.1.1.7 viruses.

A novel SARS-CoV-2 lineage B.1.1.7 was recently identified and shown to be rapidly expanding across the UK, particularly in London and in the southeast and the east of England (1, 2) . This lineage was detected in November 2020 and likely originated in September 2020 in Kent, southeast England. B.1.1.7 viruses possess a striking constellation of nucleotide changes with an unusual number of missense mutations in the spike protein of potential biological relevance (3) (Fig. 1) . For this reason, lineage B.1.1.7, was designated SARS-CoV-2 variant of concern (VOC) 202012/01 by Public Health England (PHE) since the mutations found might impact transmission, immune response, and disease severity. Mutation N501Y, located within the receptor-binding domain (RBD), can increase binding affinity to human and murine angiotensin-converting enzyme 2 (ACE-2) receptor and cell infectivity in mice (4) (5) (6) . Substitution P681H is immediately adjacent to the furin cleavage site, important for viral pathogenesis (7, 8) , whereas deletion of amino acids 69 and 70 has been identified in multiple lineages associated with different RBD mutations and has been related to the evasion to human immune response (9) . The deletion of nucleotides 21765 to 21770 coding for amino acids 69 and 70 has been associated with S-gene target failure (SGTF) in diagnostic PCR testing of samples showing positive results for other gene targets (1) and is used to estimate the proportion of COVID-19 confirmed cases likely associated with infection by variant B.1.1.7. Epidemiological evidence and phylogenetic analysis of viral sequences suggest that viruses of the B.1.1.7 lineage may have increased transmissibility compared to ancestral isolates (2) . Whole-genome sequencing and SGTF data have shown a rapid increase in the prevalence of B.1.1.7 variant through time with the proportion of sequences from clinical samples associated with B.1.1.7 in England, reaching around 94% during the last week of January 2021 (1, 2, 10) . Additional analyses indicate exponential growth of lineage B.1.1.7 and an increase of between 0.4 and 0.7 in the reproduction number with respect to previous lineages (2) .

Other VOCs have been identified recently, notably lineages B.1.351 and P.1, known to be circulating in South Africa since early October 2020 (11) and in Brazil since early December 2020 (12) , respectively, and also containing complex mutation constellations, including an N501Y amino acid change (Fig. 1) . B.1.351 and P.1 variants have two more spike mutations of biological significance: E484K and K417N/T, both located in the RBD and both important for ACE-2 binding and antibody recognition. Mutations at spike amino acid 484 have been shown to reduce binding to convalescent-phase serum antibodies, with neutralization by some sera reduced .10-fold (13) . Amino acid substitutions at residue 417, K417N in B.1.351 and K417T in P.1, appear to improve evasion from antibodies in combination with N501Y and E484K (14) . More recently, mutation E484K has been identified in a small number of B.1.1.7 viruses in England (15) , raising increased concerns about this variant. The effects of mutations found in the VOCs detailed above suggest that VOCs could be a threat to the protective efficacy of current vaccines by reducing vaccine-induced immunity against them. Recent research has shown that while B.1.1.7 is modestly resistant to sera from vaccinees, B.1.351 is markedly more resistant to neutralization by such sera, and some COVID-19 vaccines appear to show reduced efficacy against this variant (16) (17) (18) (19) (20) . Although further research is required to fully understand the effect of spike mutations on vaccine efficacy, updating vaccine strains might be required in the future in a similar manner to what is common practice for flu vaccines.

The appearance and rapid growth of VOCs shows the need for enhanced genomic and epidemiological surveillance worldwide to ensure that any new changes in the spike protein that might arise are rapidly detected and their biological effects investigated. Environmental surveillance (ES) has proven to be a sensitive method for the detection and monitoring of SARS-CoV-2 circulation, as described in multiple reports from many countries (reviewed in reference 21). Since ES can produce a real-time snapshot of virus transmission at a given time point, including that from asymptomatic infections, it might provide precise information on the prevalence of VOCs in the population. We were able to detect SARS-CoV-2 viral RNA in sewage samples collected in London during the first wave of the pandemic with variation in viral RNA levels comparing to that of numbers of confirmed COVID-19 cases (22) . In addition, using next-generation sequencing (NGS) analysis of PCR amplicons generated from sewage concentrates, we were able to track changes in variant predominance during the first stages of the pandemic detecting variants that were particularly prevalent in the UK and the rapid expansion of D614G variant reaching nearly complete dominance in May 2020 (22) . This variant contains a mutation from A to G at nucleotide 23403, resulting in amino acid change from aspartic acid to glycine at residue 614 of the spike protein, which appeared to increase viral infectivity and transmissibility. Variant D614G was first described in late February 2020 in Italy, rapidly expanding and becoming the dominant SARS-CoV-2 variant globally a few months later (23) . Similar work by other groups has described the detection of cocirculating SARS-CoV-2 variants in sewage samples from different locations, including a recent report describing the identification of B.1.1.7 lineage in sewage samples from Switzerland (24) (25) (26) (27) (28) .

In order to further evaluate the value of ES for SARS-CoV-2 detection, we analyzed sewage samples collected in London between 14 January 2020 and 26 January 2021 for the presence of SARS-CoV-2 by using a semiquantitative nested reverse transcription-PCR (nPCR) system targeting two different genomic regions since we have found this system to be more sensitive and consistent than quantitative RT-PCR assays (22) . More importantly, we have designed new nPCR reactions to generate DNA amplicons and analyze them by NGS in order to specifically detect and quantify the presence of key mutations that discriminate lineages B.1.1.7, B1.351, and P.1 from ancestral isolates and between themselves.

nPCR amplifications to estimate SARS-CoV-2 RNA levels in sewage samples. Twelve RNA replicates from each sewage concentrate were used to generate nPCR products with primer combinations A and B (see Table S1 in the supplemental Fig. 2 in the context of epidemiological data. As we have shown before, a sample from 14 January 2020 was negative, and only low levels of viral NGS analysis of nPCR products for the detection of SARS-CoV-2 B.1.1.7, B1.351, and P.1 lineages. Twelve additional RNA replicates from each sewage concentrate were used to generate nPCR products with primer combinations C and D (see Table S1 ), mapping in the spike protein gene. All amplicons from positive nPCR reactions were analyzed by NGS with an aim to detect and quantify nucleotide sequence variations specifically found in B.1.1.7, B1.351, and P.1 lineages (Table 1) . Nucleotide sequences characteristic of lineage B.1.1.7 were detected in sewage samples from 10 November 2020 onward. Mean sequence frequency values at key nucleotide positions, calculated from all sequenced replicates for each monthly sewage sample, are shown in Fig. 3 . The results show that mutations discriminating the B.1.1.7 lineage from ancestral isolates, which include relevant mutations coding for amino acid changes and amino acid deletions (Table 1) , clearly increased in frequency between November 2020 and January 2021 from 6.8 to 8.9% on 10 November to 44.0 to 46.4% on 8 December 2020, 93.6 to 94.1% on 12 January 2021, and 95.2 to 98.8% on 26 January 2021. It is worth noting that all four mutations analyzed showed very similar frequencies between them at any given time, reinforcing the conclusion that they all correspond to an increment of B.1.1.7 lineage through time. An example of NGS results showing an increasing proportion of a nucleotide 21765-21770 deletion (deletion of amino acids HV69-70) in viral RNAs from sequential sewage samples is shown in Fig. S1 . It is important to emphasize that when analyzing surveillance data in real time, clinical surveillance has a potential limitation with respect to environmental surveillance since only a fraction of clinical samples is subjected to whole-genome sequence analysis. If 5% or fewer positive clinical samples are sequenced and the prevalence of B.1.1.7 or any other variant of interest in the population is 5%, at least 400 samples would need to be sequenced to find one such virus by chance. The time lapse between infection and symptoms developing, as well as samples taken and being tested, would add further delays compared to the expected immediacy of results from sewage surveillance.

Estimates of B.1.1.7 prevalence based on NGS data were in very good agreement with those from whole-genome sequencing and SGTF data from clinical samples from London and England (1, 2); according to the GISAID sequence database (10), the frequency rates of B.1.1.7 sequences from England during the week before and the week after sewage sample collection were 3.4 and 7.3% for 10 November, 25 80 Table S1 in the supplemental material. Abbreviations: nt, nucleotides; aa, amino acids.

differences were found between B.1.1.7 frequency estimates obtained from sewage using data from any of the four mutations analyzed for any of the five sampling dates (t test, P . 0.05) (see Table S3 ). A good correlation between B.1.1.7 frequency estimates from mutation analysis of viral RNAs from sewage and clinical data was observed throughout the period of study, with B.1.1.7 frequency increasing from ,0.1% in October to .95% in late January and r 2 values ranging between 0.968 and 0.997 (Table 2 ). There was better agreement between sewage and clinical data when using data from clinical samples corresponding to the week after sewage sample collection than to the week before, with sewage and clinical data superimposing almost perfectly when represented in the same graph (Fig. 4 ) and small differences between B.1.1.7 frequency estimates from sewage and clinical data representing only between 1.04 and 17.30% of the actual sewage frequency values versus between 5.92 and 61.46% when using clinical data from the week before (Table 2 ). In any case, this interpretation has to be taken with caution because sewage data corresponding to London, with a catchment area of approximately 4.0 Â 10 6 people, were compared to sequencing data from the whole of England, since no sequence data specific for London are publicly Table 2 . Statistical values associated with these data are shown in Table S2. available. Because different regions showed different timelines of B.1.1.7 introduction and growth, the comparison presented above might not be totally accurate. However, results from recent reports show that whole-genome sequencing and SGTF data from clinical samples from London resemble those for the whole of England very closely (1, 2) . In contrast, none of the nucleotide substitutions unique to B.1.351 and P.1 lineages (Table 1) were detected in any of the replicate nPCR products from any of the sewage samples. Additional nucleotide sequence variations were found at different sites in amplicons from sewage samples (Table 3) , but none followed the same pattern as that observed with B.1.1.7 mutations, which were repeatedly detected in replicate viral RNA sequences and consistently found in sequential samples in increasing proportions. Interestingly, additional sequence variations most frequently found in viral RNA replicates from the same or different sampling dates mapped at locations adjacent to mutations characteristic of variant B.1.1.7 in the spike protein three-dimensional (3D) structure (Fig. 5) : mutation S98F is located next to amino acid 69, which is deleted in variant B.1.1.7; substitution D574Y maps next to amino acid 570, which changes from alanine (A) to aspartic acid (D) in B.1.1.7 viruses; and mutations T478A, F490S, and S494P locate in the RBD, near amino acid 501, which changes from asparagine (N) to tyrosine (Y) in B.1.1.7. Most of these mutations have been found in clinical isolates from England, some of them in relatively large numbers, such as S98F and S494P (Table 3) .

Sanger sequence analysis of nPCR products. Selected PCR products from nPCR reactions A and B were analyzed by Sanger sequencing to confirm the SARS-CoV-2 genome sequence. nPCR product B contains codon GAT at nucleotide position 28280, which changes to CTA in B.1.1.7 lineage viruses, resulting in the amino acid substitution aspartic acid to leucine at residue 3 of the nucleocapsid (N) protein. Hence, nPCR product B can also be used to identify and quantify B.1.1.7 sequences in sewage samples. The Sanger sequence analysis revealed that B.1.1.7 codon CTA was not present in replicate viral sequences from sewage concentrates from September (0/6) and October 2020 (0/4) but was detected in replicate samples from November 2020 (1/4), December 2020 (2/3), and January 2021 (2/2) in agreement with the results of NGS analysis of nPCR products C and D described above. 

We were able to detect SARS-CoV-2 RNA in sewage samples from London throughout the COVID-19 pandemic, with changes in viral RNA levels shown to be in good agreement with those of confirmed COVID-19 cases reflecting national restrictions (Fig. 2) . The second lockdown period lasting from 5 November to 2 December appear to only have had a limited effect in reducing virus transmission which, together with the emergence of the apparently highly transmissible B.1.1.7 variant, may explain the high levels of viral RNA found in sewage and the high number of SARS-CoV-2 infections reported in England in December 2020 and January 2021. In England 1 in 50 people (1 in 30 in London) were estimated to have had SARS-CoV-2 infection in the week ending 2 January according to an infection survey by the Office for National Statistics (29) . The third nationwide lockdown initiated on 4 January 2021 is having a clear effect at reducing virus transmission, as judged by the observed drop in COVID-19 confirmed cases, but as of 26 January 2021, SARS-CoV-2 RNA levels remained high in sewage (Fig. 2) , reflecting the extent of virus transmission occurring during the second phase of the second wave of the COVID-19 epidemic. Although detailed quantification of SARS-CoV-2 RNA in sewage and its correlation with COVID-19 infection prevalence was outside the scope of the present study and would require more frequent and widespread sampling, our results suggest that high viral RNA concentration levels could be Table 2 . Statistical values associated with these data are shown in Table 2 and Table S3 . Panels A to D are as defined for Fig. 3 . detected preceding peaks in COVID-19 confirmed cases, showing the potential predictive value of ES, as has been shown in other studies (21) . NGS analysis of DNA amplicons directly synthesized from SARS-CoV-2 RNA present in sewage concentrates from London allowed us to readily identify viruses belonging to B.1.1.7 lineage before widespread transmission of this variant was obvious. We were able to detect B.1.1.7 variant at a frequency of 6.8 to 8.9% in a sample collected on 10 November 2020, a few weeks before it was first noticed through clinical surveillance. The B.1.1.7 variant first became apparent in late November 2020 when PHE was investigating why infection rates in Kent remained high despite national restrictions. A concerning cluster of virus isolates showing an unusual constellation of mutations was then found that could explain the persistent high infection rates (3, 15) . Retrospective analysis showed that the two earliest genomes belonging to B. the sewage samples, which was expected since only a small number of B.1.351 isolates had been found in England at that time, not necessarily in London, and no P.1 viruses had been detected in the UK yet. The G23012A nucleotide substitution present in both B.1.351 and P.1 lineages and responsible for spike amino acid change E484K, thought to play a critical role at changing virus antigenicity and reducing human immune response to the virus and vaccine efficacy (13, (16) (17) (18) (19) (20) , was not detected in viral genomes from sewage. This mutation has recently been found in a small number of B.1.1.7 isolates in England but mostly in locations away from London (15) . We expect that the methods shown here can help to rapidly identify such mutants, as well as B.1.351 and P.1 lineages, in the same way that we have identified B.1.1.7 viruses (Table 1) . We did find additional mutations in low frequency at amino acid sites of possible biological relevance located close to mutations characteristic of variant B.1.1.7 in the spike protein 3D structure; most of these are known to be present in clinical isolates from England. Mutations T478A, F490S, and S494P, in particular, are located very close to amino acid 484, known to have an effect on virus antigenicity, as discussed above. Similarly, mutations at these three sites have been shown to be associated with weaker neutralization to the virus by sera from convalescent people who have been infected with SARS-CoV-2 and/or monoclonal antibodies that could be used to patients with COVID-19 (30) (31) (32) (33) (34) . It is important to monitor the appearance and to quantify the prevalence of such additional mutations since they might represent a challenge for vaccine efficacy. As shown in this study, ES appears to be a suitable system for such purpose. An early assessment of the biological effect of mutations of concern found to be prevalent in successive samples would be critical. These methods can also be used to sequence SARS-CoV-2 in clinical samples using traditional Sanger sequencing for the rapid identification of VOCs in settings where wholegenome sequencing capabilities are limited. New PCRs can be quickly designed to track down new VOCs that might arise anywhere and detect importations. Furthermore, systematic sequencing of the spike gene of viral RNAs present in sewage samples collected regularly would help in proactively identifying potential new VOCs based on mutations and trends encountered. Eventually, if vaccine strains need to be regularly updated, as is current practice with flu vaccines, ES could be a useful resource to help vaccine strain selection based on prevalent SARS-CoV-2 variants circulating around the world.

As shown here, ES has a potential advantage for the early detection of VOCs versus clinical surveillance because it provides an immediate snapshot of virus transmission events representing thousands/millions of people, including asymptomatic infections. The methods shown here can provide sequencing results within 1 week of sewage samples arriving in the laboratory. According to the GISAID sequence database (10), only 33 B.1.1.7 sequences had been identified on 16 November 2020 in England, 1 week after the collection date of our first positive sewage sample. Even in the context of the phenomenal SARS-CoV-2 sequencing program established in England, clinical surveillance requires some time to build up enough data representative of current transmission patterns that is comparable to that provided by ES. In addition, since most clinical testing is based on samples from symptomatic infections, a delay of several days is expected between initial infection and viral sequence data availability due to the time required for symptoms to develop, samples to be collected, and PCR/ sequencing analyses to be completed. Clinical surveillance is highly dependable on rapid and widespread PCR testing, as well as an extensive whole-genome sequencing program. This is currently only happening in a few countries so, in most locations, ES could be a major asset for monitoring SARS-CoV-2 virus circulation and identifying VOCs. After preparation of this manuscript, we recently detected a clear decline in the proportion of B.1.1.7 lineage in a sewage sample from April 2021 for the first time since it became dominant in late January 2020 and a concurrent increase in the presence of non-B.1.1.7 VOCs such as B.1.351 and B.1.525 (further research is in progress). On the other hand, identification of locally circulating VOCs could be delayed using ES at sites that cover very large populations, and therefore community-based ES targeting smaller populations would increase the sensitivity for detection of such VOCs, e.g., current efforts to track down transmission of B.1.1.7 viruses harboring mutation E484K in England could be helped by community-based ES in areas where isolation of such viruses are known to have occurred.

Wastewater sample collection and processing. One-liter inlet wastewater composite samples were collected during a 24-h period at a sewage plant in London with a catchment area of approximately 4.0 Â 10 6 people. Monthly samples collected every second Tuesday of the month were collected between 14 January 2020 and 12 January 2021, with an additional sample collected on 26 January 2021. Each sample was processed using a filtration-centrifugation method described before (22) . Briefly, following removal of solids by centrifugation at 3,000 Â g, raw sewage was filtered through a 0.45-mm filter (Nalgene 500-ml Rapid-Flow) and concentrated down from 70 ml to 200 to 400 ml using Merck Millipore Centricon Plus-70 centrifugal filter units with a 10-kDa molecular weight cutoff (Merck) according to the manufacturer's instructions. Samples from January to May 2020 reported previously (22) were reanalyzed in this study.

nPCR amplifications. Viral RNA was purified from sewage concentrates using the High-Pure viral RNA kit (Roche). RT-PCR fragments were amplified from purified viral RNAs using an nPCR system described before consisting of a one-step RT-PCR, followed by a second PCR using the first PCR product as the template (22) . The genome location and nucleotide sequences of primer sets used for the nPCR reactions are shown in Table S1 . Primer sets A and B targeting RdRP and ORF8b gene regions were used for diagnostic nPCRs. Primer sets C and D targeting spike gene regions were used for the detection of B.1.1.7, B.1.351, and P.1 lineages. As shown in Table 1 , sequence analysis of nPCR C and D products can discriminate between B.1.1.7, B.1.351, and P.1 lineages and between them and ancestral isolates. Primers were tested using serial dilutions of purified RNA from the National Institute for Biological Standards and Control (NIBSC)'s virus reagent 19/304 containing noninfectious synthetic SARS-CoV-2 RNA packaged within a lentiviral vector (https://www.nibsc.org/products/brm_product_catalogue/detail _page.aspx?catid=19/304). Twelve RNA aliquots from each sewage sample were used for nPCR amplifications for each nPCR reaction. Good laboratory practices were observed in all assays to reduce the possibility of cross-contamination, using different laboratory locations for sample processing, preparation of reaction mixtures, template addition, and postprocessing analysis. RNA extraction and negative template controls were included in every assay. Selected purified DNA amplicon products were sequenced by the Sanger method using an ABI Prism 3130 genetic analyzer (Applied Biosystems).

NGS analysis of nPCR products. Sequencing libraries were constructed by A/T adapter ligation using the KAPA HyperPrep kit (Roche, Switzerland) and dual-indexed using IDT TruSeq DNA unique dual indexes (Illumina, USA) with five PCR cycles for library amplification. These libraries were pooled in equimolar concentrations according to manufacturer's instructions and sequenced with 250-bp paired-end reads on MiSeq v2 (500 cycles) kits (Illumina). Initial demultiplexing was performed on-board by the MiSeq Reporter software. FASTQ sequencing data were adapter and quality trimmed by Cutadapt v2.10 (35) for a minimum Phred score of Q30, minimal read length of 75 bp, and 0 ambiguous nucleotides.

Generation of SARS-CoV-2 sequence contigs and identification of single nucleotide polymorphisms. Further processing and analysis of NGS data were performed using Geneious 10.2.3 software as described before (22) . Filtered reads were imported into Geneious 10.2.3, paired-end reads were combined and merged, and sequence contigs were built by reference-guided assembly. Reads were mapped to references with a minimum 50-base overlap, minimum overlap identity of 90%, maximum 10% mismatches per read, allowing up to 15% gaps, and index word length of 12. Single nucleotide polymorphisms (SNPs) were identified using Geneious 10.2.3 default settings. The original SARS-CoV-2 Wuhan-Hu-1 strain (GenBank accession number MN908947) was used as a reference. Variants with coverage ,500, average quality ,30, variant frequency ,5%, and strand-bias P . 10 26 were excluded. The analysis of several amplicon replicates per sample is critical to reduce sampling effects and increase the accuracy of SNP determinations for viral genomes present in a given sewage sample. If we set up a conservative limit of 5% for any SNP found in any replicate amplicon sequence to be accepted as genuinely present in viral RNAs, and given that we sequenced 12 independent RNA replicates per sample and nPCR reaction, the limit of detection for detecting a sequence variant would be approximately 0.42%, which seems reasonably low for the early detection of the spread of SARS-CoV-2 variants of potential concern. If we consider sequencing 5% of all positive clinical samples as a minimum requirement, which is currently only achieved in a few countries, a 0.42% prevalence of a variant would mean finding 21 to 105 viruses among 10,000 to 50,000 new daily positive cases, respectively. However, for clinical surveillance to be representative and have comparable sensitivity to ES, widespread and consistent clinical sampling across the sewage catchment area would be needed.

SARS-CoV-2 nucleotide sequence analysis and estimates of the prevalence of B.1.1.7 lineage among whole-genome sequences from clinical samples. SARS-CoV-2 sequences obtained in this study were compared to those available in the Global Initiative on Sharing All Influenza Data (GISAID) SARS-CoV-2 sequence database (10) . The COVID-19 Genomics (COG-UK) Consortium/Mutation Explorer with sequencing data generated by 28 February 2021 (http://sars2.cvr.gla.ac.uk/cog-uk/) was also used to examine the presence and proportion of selected viral amino acid variations in clinical samples. Geneious version 10.2.3 software (Biomatters) was used for these analyses. Estimates of the proportion of viruses belonging to B.1.1.7 lineage at different time points in England were obtained using the GISAID SARS-CoV-2 sequence database (10) with results available on 1 March 2021.

Statistical analysis. Statistical analysis and graphical representation of variant sequence frequency data were conducted using GraphPad Prism version 8.1.2 software. Statistical significance was determined using the Holm-Sidak method, with alpha = 0.05.

Data availability. FASTQ files used in this study are available from the NCBI Short Read Archive under project code PRJNA712959.

Supplemental material is available online only. FIG S1, PDF file, 0.6 MB. 

Investigation of novel SARS-CoV-2 variant: variant of concern 202012/01

The COVID-19 Genomics UK (COG-UK) Consortium. 2021. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England

Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations

An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants

Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy

A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells

Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis

Recurrent emergence and transmission of a SARS-CoV-2 spike deletion H69/V70

Data, disease, and diplomacy: GISAID's innovative contribution to global health

Detection of a SARS-CoV-2 variant of concern in South Africa

Genomic characterization of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Impact of South African 501.V2 variant on SARS-CoV-2 spike infectivity and neutralization: a structure-based computational assessment

Investigation of novel SARS-CoV-2 variant of concern 202012/01: technical briefing 5

2021. mRNA-1273 vaccine induces neutralizing antibodies Identification of New SARS-CoV-2 global SARS-CoV-2 variants

2021. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

SARS-CoV-2 from faeces to wastewater treatment: what do we know? A review

Tracking SARS-CoV-2 in sewage: evidence of changes in virus variant predominance during COVID-19 pandemic

Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus

High-throughput sequencing of SARS-CoV-2 in wastewater provides insights into circulating variants

Temporal detection and phylogenetic assessment of SARS-CoV-2 in municipal wastewater

Genome sequencing of sewage detects regionally prevalent SARS-CoV-2 variants

Detection of SARS-CoV-2 variants in Switzerland by genomic analysis of wastewater samples

Monitoring SARS-CoV-2 circulation and diversity through community wastewater sequencing

Office for National Statistics. 2021. Coronavirus (COVID-19) Infection Survey

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

An engineered antibody with broad protective efficacy in murine models of SARS and COVID-19

Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Atropos: specific, sensitive, and speedy trimming of sequencing reads

Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM

We thank Mihaela Cirdei, Ola Miloszewska, and Julian Hand from Public Health England for arranging the collection and transport of raw sewage samples.This study is based on independent research commissioned and funded by the NIHR Policy Research Program (NIBSC Regulatory Science Research Unit). The views expressed in the publication are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health, "arms" length bodies, or other government departments.